Rescuing cardiac automaticity in L-type Cav1.3 channelopathies and beyond

Pietro Mesirca1,2,3, Isabelle Bidaud4,5,6, Matteo E Mangoni7,8,9

  • 1Département de Physiologie, Institut de Genomique Fonctionnelle, LabEx ICST, UMR-5203, Centre national de la recherche scientifique, F-34094, Montpellier, France. pietro.mesirca@igf.cnrs.fr.

Insights

Sick sinus syndrome (SSS) causes slow heart rate and is treated with pacemakers. Targeting compensatory ion channels, like IKACh, may offer new therapies for SSS and bradycardia.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Sick sinus syndrome (SSS) is a leading cause of bradycardia, necessitating pacemaker implantation.
  • The incidence of SSS is projected to double in 50 years, highlighting the need for novel therapeutic strategies.
  • Mutations in ion channels, particularly L-type Cav 1.3 channels, are implicated in inherited SSS.

Purpose of the Study:

  • To investigate novel therapeutic targets for SSS beyond conventional pacemaker therapy.
  • To explore the role of compensatory ion channel modulation in restoring sino-atrial node function.

Main Methods:

  • Utilized a mouse model (Cav 1.3-/-) that recapitulates key features of SSS.
  • Investigated the effects of targeting G protein-gated K+ (IKACh) channels in the Cav 1.3-/- mouse model.

Main Results:

  • Cav 1.3 channel deficiency in mice mimics SSS, providing a valuable preclinical model.
  • Targeting IKACh channels successfully rescued SSS phenotypes in Cav 1.3-/- mice.

Conclusions:

  • Modulating compensatory ion channels presents a promising therapeutic avenue for SSS.
  • This approach offers a new perspective on pacemaker mechanisms and potential treatments for bradycardia.

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Cardiac Action Potential01:30

Cardiac Action Potential

Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
8.3K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.5K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
835
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.1K